RxDoctor Payments Data

Benjamin Herrick, MD

Urology · Greensboro, NCNPI 1588838965

Payments from drug & device makers

$3,643in general payments, 2019–2025

Across 169 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$942
  • Astellas Pharma US Inc$478
  • Johnson & Johnson$371
  • Dendreon Pharmaceuticals LLC$353
  • Pfizer$193
  • Sumitomo Pharma America, Inc.$189
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$57916%
  • Food & beverage$2,88679%
  • Education$1785%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,643 in reported general payments places this provider in the 55th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$153,203
Medicare patients
392
Services billed
4,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron346$188,502
GemtesaVibegron114$75,379
Tamsulosin Hcl1,111$15,397
Methenamine Hippurate55$4,268
Estradiol60$4,155
Testosterone68$4,061
Finasteride287$3,342
Testosterone Cypionate40$3,156
Alfuzosin Hcl ErAlfuzosin Hcl90$1,958
Solifenacin Succinate63$1,844
NitrofurantoinNitrofurantoin Macrocrystal36$1,565
Silodosin18$1,467
Tolterodine Tartrate ErTolterodine Tartrate16$912
Cephalexin70$750
Trimethoprim15$559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$478$188,502346 claims
Sumitomo Pharma America, Inc.Gemtesa$189$75,379114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 434 urology providers in North Carolina.

Other urology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →